Streetbeat News

Earnings

BAND

Bandwidth has provided its Q4 and FY24 revenue guidance. The company expects Q4 revenue to be between $198M and $208M, surpassing the estimated $189.67M. However, its FY24 revenue guidance of $737M-$747M falls short of the $748.53M estimate.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:38 am

ETN

Eaton has released its Q4 2024 financial expectations, forecasting adjusted EPS between $2.78 and $2.84, slightly above the consensus estimate of $2.81. The company also anticipates organic growth of 6-7% and segment margins of 23.6-24.0%.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:38 am

TFX

Teleflex has revised its FY24 financial guidance, lowering its GAAP revenue growth range and slightly adjusting its EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:38 am

VRN

Veren (NYSE:VRN) reported Q3 2024 earnings per share of C$0.29, missing the estimate of C$0.30, but sales of C$992.9M exceeded the estimate of C$950.95M. Earnings decreased by 50.85% from last year, while sales slightly decreased by 0.58%.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:36 am

ETN

Eaton has raised its 2024 guidance, now expecting adjusted EPS of $10.75-$10.81, up from the previous $10.65-$10.75. The company also increased its segment margins and overall EPS expectations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:36 am

UTZ

Utz Brands has reaffirmed its outlook for FY24, expecting organic net sales growth of 2%-2.5% and projecting adjusted earnings per share growth of 28%-32%.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:35 am

CMS

CMS Energy has reaffirmed its 2024 adjusted earnings guidance, projecting earnings per share between $3.29 and $3.35, aligning closely with the consensus estimate of $3.33.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:35 am

CMPS

Compass Pathways reported a Q3 2024 GAAP EPS of $(0.56), which was in line with analyst expectations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:34 am

REGN

Regeneron Pharmaceuticals has announced that its fiscal year 2024 non-GAAP gross margin on net product sales is expected to be approximately 89%, which remains unchanged from previous guidance.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:34 am

IDA

Idacorp reported Q3 2024 earnings per share of $2.12, missing the analyst consensus estimate of $2.18 by 2.75%.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 10:33 am